Alprazolam C-IV — Class II drug recall D-0508-2023
Ongoing recall by Direct Rx, reported 2023-04-12, distributed nationwide. CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manuf
| Recall number | D-0508-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Direct Rx, Dawsonville, GA, United States |
| Recall initiated | 2023-03-22 |
| Classified | 2023-04-06 |
| Reported by FDA | 2023-04-12 |
| Distributed | Nationwide (US) |
| Quantity | 349 bottles |
| Reason classes | cgmp |
| NDC | 72189-0213-30, 72189-0213-60 |
| Expiration dates | 2023-03-31, 2023-05-31, 2023-06-30, 2024-08-31, 2024-09-30, 2024-11-30 |
Product
Alprazolam C-IV, 1 mg, packaged in a) 30 Tabs per bottle, NDC 72189-213-30; b) 60 Tabs per bottle, NDC 72189-213-60; Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534.
Reason for recall
CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0508-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.